These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 6850662)

  • 1. Phase I trial of mitoxantrone by 24-hour continuous infusion.
    Anderson KC; Garnick MB; Meshad MW; Cohen GI; Pegg WJ; Frei E; Israel M; Modest E; Canellos GP
    Cancer Treat Rep; 1983 May; 67(5):435-8. PubMed ID: 6850662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione).
    Wynert WR; Harvey HA; Lipton A; Schweitzer J; White DS
    Cancer Treat Rep; 1982 Jun; 66(6):1303-6. PubMed ID: 7083234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and clinical pharmacologic studies of mitoxantrone.
    Stewart JA; McCormack JJ; Krakoff IH
    Cancer Treat Rep; 1982 Jun; 66(6):1327-31. PubMed ID: 7083236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of JM9 in advanced ovarian cancer: a phase I-II trial.
    Bramwell VH; Crowther D; O'Malley S; Swindell R; Johnson R; Cooper EH; Thatcher N; Howell A
    Cancer Treat Rep; 1985 Apr; 69(4):409-16. PubMed ID: 3995511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of ICRF-187 by 48-hour continuous infusion.
    Koeller JM; Earhart RH; Davis HL
    Cancer Treat Rep; 1981; 65(5-6):459-63. PubMed ID: 6786740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I investigation of ametantrone.
    Loesch DM; Von Hoff DD; Kuhn J; Coltman CA; Tio F; Chaudhuri TK; Bender JF; Grillo-Lopez AJ
    Cancer Treat Rep; 1983 Nov; 67(11):987-91. PubMed ID: 6640557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose mitoxantrone in metastatic breast cancer: a phase I-II trial.
    Leiby JM; Unverfurth DV; Neidhart JA
    Cancer Treat Rep; 1986 Jul; 70(7):899-901. PubMed ID: 3719583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of menogaril administered as an intermittent daily infusion for 5 days.
    Sigman LM; Van Echo DA; Egorin MJ; Whitacre MY; Aisner J
    Cancer Treat Rep; 1986 Jun; 70(6):721-5. PubMed ID: 2942244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
    Nicaise C; Rozencweig M; Crespeigne N; Dodion P; Gerard B; Lambert M; Decoster G; Kenis Y
    Cancer Treat Rep; 1986 May; 70(5):599-603. PubMed ID: 3708609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
    Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone and cyclophosphamide in patients with advanced breast cancer.
    Ehninger G; Weible KH; Heidemann EG; Waller HD
    Cancer Treat Rep; 1984 Oct; 68(10):1283-4. PubMed ID: 6525600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
    Sampi K; Kaneko Y; Maseki N; Kumai R; Sakurai M; Hattori M
    Gan To Kagaku Ryoho; 1985 Jul; 12(7):1453-7. PubMed ID: 4015120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of mitoxantrone in children.
    Ungerleider RS; Pratt CB; Vietti TJ; Holcenberg JS; Kamen BA; Glaubiger DL; Cohen LF
    Cancer Treat Rep; 1985 Apr; 69(4):403-7. PubMed ID: 3857968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.
    Von Hoff DD; Pollard E; Kuhn J; Murray E; Coltman CA
    Cancer Res; 1980 May; 40(5):1516-8. PubMed ID: 7370989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical study of dihydroxyanthracenedione administered on a 5-day iv schedule.
    Valdivieso M; Bedikian AY; Burgess MA; Savaraj N; Jeffers WB; Bodey GP
    Cancer Treat Rep; 1981; 65(9-10):841-4. PubMed ID: 7273017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of mitoxantrone in refractory acute leukemia.
    Estey EH; Keating MJ; McCredie KB; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1983 Apr; 67(4):389-90. PubMed ID: 6850655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial clinical study with vindesine: tolerance to weekly iv bolus and 24-hour infusion.
    Ohnuma T; Greenspan EM; Holland JF
    Cancer Treat Rep; 1980 Jan; 64(1):25-30. PubMed ID: 6929728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
    Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
    Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-day infusion.
    Lokich J; Corkery J
    Cancer Treat Rep; 1981; 65(9-10):887-9. PubMed ID: 7273024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.